Axon Ligands (TM) - alphabetic: [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z]

CDIBA

CAS 479422-22-5

C31H26ClNO3 MW 496.00

Purity: 99 %

Ordering Information:

Cat. No. Axon 1609   Prime Source

Qty1: 5 mg / €125  $163

Promotion: 2 x 5 mg @ €180  $234

Qty2: 25 mg / €425  $553

Promotion: 2 x 25 mg @ €620  $806

Qty3: on request

Send enquiry to: order@axonmedchem.com

or by fax to: +31-50-3600390.

Contact us for payment and tech support.

Biological Activity:   Potent and selective cytosolic phospholipase A2 (cPLA2) inhibitor   References:   Novel Target for Existing Drug May Improve Success of Radiation Therapy. ScienceDaily Sep. 20, 2010. [online]   AG Linkous et al. Cytosolic Phospholipase A2 and Lysophospholipids in Tumor Angiogenesis. J. Natl. Cancer Inst. 2010; 102(18), 1398-1412. [online]     Chemical Name: 4-[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]-ethoxy]benzoic acid

CDIBA | cPLA2 inhibitor | Axon Medchem | Axon 1609

Axon Ligands TM - Research chemicals for biological study. Some high-profile samples could be provided under terms of contract research synthesis.

axonmedchem.com © 2012

Axon Ligands In The Field:

CDIBA | cPLA2 inhibitor

U 73122 | PLC inhibitor

About cPLA2

The enzyme cPLA2 promotes development and functioning of blood vessel networks that feed malignant tumors, enabling them to overcome the effects of radiation. Inhibition of cPLA2 leads to collapsed vessels, stopping blood flow to the tumor.